| DC10062 |
MBP146-78
Featured
|
MBP146-78 inhibits the growth of Eimeria spp. both in vitro and in vivo. |
|
| DC7193 |
MBX-2982
Featured
|
MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes. |
|
| DC10872 |
MBX-4132
Featured
|
MBX-4132 a trans translation inhibitor by binding to the bacterial ribosome. |
|
| DC5128 |
MC1568
Featured
|
MC1568 is a class II (IIa) HDAC inhibitor selective for HDAC4 and HDAC6 |
|
| DC12527 |
MC180295
Featured
|
MC180295 (MC-180295, MC 180295) is a novel potent, highly selective CDK9 inhibitor with IC50 of 5 nM, displays >22-fold selectivity over other CDKs. |
|
| DC10940 |
MC3343
Featured
|
MC3343 (MC-3343) is a novel potent, non-nucleoside DNA methyltransferase (DNMT) inhibitor with IC50 of 5.7 and 1.7 uM for DNMT1 and DNMT3a. |
|
| DC11338 |
MMP-2/MMP-7 Fluorogenic Substrate Control
Featured
|
Mca-PL is a fluorogenic peptide that has been used as a building block in the synthesis of Mca-PLGL-Dpa-AR-NH2, a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-7. |
|
| DC8550 |
MCB-613
Featured
|
MCB-613 is a novel and potent stimulator of p160 steroid receptor coactivators (SRCs). It is a Pan-SRCs stimulator. |
|
| DC23706 |
Netoglitazone(MCC 555)
Featured
|
Netoglitazone, also known as isaglitazone and MCC-555, is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Netoglitazone exerts both peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist activity. Netoglitazone decreases bone formation and increases marrow adipocyte formation in vivo.MCC 555 (Isaglitazone. |
|
| DC26109 |
MCL0129 tetrahydrochloride
Featured
|
MCL0129 is a selective, potent melanocortin-4 receptor (MC4R) antagonist with Ki of 7.9 nM, without affinity for MC1 and MC3. |
|
| DC23820 |
MCP110
Featured
|
MCP110 is a potent Ras/Raf-1 interaction inhibitor. |
|
| DC10120 |
MC-Val-Cit-PAB
Featured
|
MC-Val-Cit-PAB, also known as MC-Val-Cit-PAB-OH, is a cathepsin cleavable ADC peptide linker. MC-Val-Cit-PAB is useful for making ADC conjugate (antibody-drug conjugate). FDA approved drugs such as brentuximab vedotin used this linker. |
|
| DC8461 |
Mc-Val-Cit-PABC-PNP（VCMMAE linker）
Featured
|
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. |
|
| DC12581 |
MDI-2268
Featured
|
MDI-2268 (MDI2268) is a small-molecule, in vivo-active inhibitor of plasminogen activator inhibitor type-1 (PAI-1), demonstrates excellent pharmacokinetics, potent activity against vitronectin-bound PAI-1 in vivo, and efficacy in murine model of venous thrombosis. |
|
| DC7743 |
Mdivi-1
Featured
|
Mdivi-1 is a selective cell-permeable inhibitor of mitochondrial division DRP1 (dynamin-related GTPase) and mitochondrial division Dynamin I (Dnm1) with IC50 of 1-10 μM. |
|
| DC10569 |
MDK1088（T.cruzi Inhibitor）
Featured
|
MDK-1088, also known as T.cruzi Inhibitor, is a Trypanosoma cruzi inhibitor. MDK-1088 has CAS#1350920-22-7 . The last 4 digit f CAS# was used in its name. |
|
| DC10573 |
MDK34597 (PI3K inhibitor)
Featured
|
MDK34597 is a PI3K inhibitor.MDK34597 is an analog of PI-103 and acts as a dual PI3K/mTOR Inhibitor. |
|
| DC10572 |
MDK35833（Oct3/4-inducer-1）
Featured
|
MDK35833, also known as Oct3/4-inducer-1, is a potent Oct3/4-inducer. |
|
| DC9297 |
MDK-5220(Orexin-2 receptor agonist)
Featured
|
MDK-5220(Orexin-2 receptor agonist) is the first selective nonpeptidic orexin 2 receptor (OX2R) agonist (OX2R EC50 = 0.023 μM, Emax = 98%; OX1R EC50 = 1.616 μM, Emax = 100%) |
|
| DC24209 |
MDK7229(MD2-IN-1)
Featured
|
MDK7229, also known as MD2-IN-1 is a MD2 (Myeloid differentiation protein 2) inhibitor. |
|
| DC10570 |
MDK74978（Multi-kinase inhibitor）
Featured
|
MDK74978, also known as Multi-kinase inhibitor I, is a Multi-kinase inhibitor. MDK74978 has CAS#778274-97-8. The last 5 digit was used in its name. |
|
| DC12028 |
MDK7526(Protein degrader 1)
Featured
|
MDK7526, also known as VHL Ligand 1; Protein degrader 1, is a potent and selective protein degrader. |
|
| DC10571 |
MDK-8582（Hnps-PLA Inhibitor）
Featured
|
MDK-8582, also known as Hnps-PLA Inhibitor, is an nhibitor of human nonpancreatic secretory Phospholipase A (hnps-PLA). |
|
| DC7194 |
MDL 29951
Featured
|
MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo. |
|
| DC5069 |
Enzalutamide (MDV3100)
Featured
|
MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM. |
|
| DC10650 |
MDVN1003
Featured
|
MDVN1003 is a potent inhibitor of BTK amd PI3K delta. |
|
| DC11141 |
ME0328
Featured
|
ME0328 is an inhibitor of PARP3 (IC50 = 0.89 µM), which is a regulator of DNA repair and mitotic progression. |
|
| DC20446 |
Mefuparib hydrochloride(CVL218)
Featured
|
Mefuparib(CVL218) hydrochloride is a potent, highly selective, competitive PARP1/2 inhibitor with IC50 of 3.2/1.9 nM, respectively.CVL218 was more potent than Remdesivir in blocking Coronavirus infection of cells and equally as potent as Remdesivir in blocking replication of virus once it has entered the cells. |
|
| DC7461 |
Meisoindigo
Featured
|
Meisoindigo(Natura-α; N-Methylisoindigotin; Dian III), a derivative of Indigo naturalis, might induce apoptosis and myeloid differentiation of acute myeloid leukemia (AML). |
|
| DC11083 |
Dersimelagon
Featured
|
Dersimelagon, also known as MT-7117 and WHO 10832, is a novel, orally-administered, small molecule, selective melanocortin-1 receptor (MC1R) agonist that increases skin melanin without sun exposure and is being developed to increase light tolerance in EPP/XLP patients. Dersimelagon significantly boosted sunlight tolerance in patients with erythropoietic protoporphyria in a multicenter, phase 2, randomized trial.
|
.jpg)
|
